Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Glioma 4Wilms Tumor 2Urothelial Cancer 2Rhabdoid Tumor 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Central Nervous System Neoplasms 2Carcinoma, Transitional Cell 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1

Interventions

Specimen Handling 6pembrolizumab 4enfortumab vedotin 4Magnetic Resonance Spectroscopy 4Gemcitabine 3cabozantinib 2Nivolumab 2Carboplatin 2Biopsy 2relatlimab 1eribulin 1erdafitinib 1avelumab 1atezolizumab 1Watchful Waiting 1Standard of Care 1Practice Guidelines as Topic 1Plasmapheresis 1Plasma Exchange 1Observation 1Lenalidomide 1Ipilimumab 1Doxorubicin 1Cystoscopy 1Contrast Media 1Cisplatin 1Central Venous Catheters 1CTLA-4 Antigen 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × erdafitinib × 90 days × Clear all
NCT04963153 2026-05-13

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡